首页> 外文OA文献 >Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle
【2h】

Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle

机译:开发和评估复制子 表达E2糖蛋白的颗粒疫苗 牛中的牛病毒性腹泻病毒(BVDV)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Bovine viral diarrhea virus is one of the most significant and costly viral pathogens of cattle worldwide. Alphavirus-derived replicon particles have been shown to be safe and highly effective vaccine vectors against a variety of human and veterinary pathogens. Replicon particles are non-propagating, DIVA compatible, and can induce both humoral and cell mediated immune responses. This is the first experiment to demonstrate that Alphavirus-based replicon particles can be utilized in a standard prime/boost vaccination strategy in calves against a commercially significant bovine pathogen.Findings: Replicon particles that express bovine viral diarrhea virus sub-genotype 1b E2 glycoprotein were generated and expression was confirmed in vitro using polyclonal and monoclonal antibodies specific to E2. Vaccine made from particles was generated in Vero cells and administered to BVDV free calves in a prime/boost regimen at two dosage levels. Vaccination resulted in neutralizing antibody titers that cross-neutralized both type 1 and type 2 BVD genotypes following booster vaccination. Additionally, high dose vaccine administration demonstrated some protection from clinical disease and significantly reduced the degree of leukopenia caused by viral infection.Conclusions: Replicon particle vaccines administered in a prime/boost regimen expressing BVDV E2 glycoprotein can induce cross-neutralizing titers, reduce leukopenia post challenge, and mitigate clinical disease in calves. This strategy holds promise for a safe and effective vaccine to BVDV.
机译:背景:牛病毒性腹泻病毒是世界范围内最重要,成本最高的牛病毒病原体之一。业已证明,源自甲病毒的复制子颗粒是针对多种人类和兽医病原体的安全且高效的疫苗载体。复制子颗粒是非繁殖的,DIVA相容的,可以诱导体液和细胞介导的免疫反应。这是第一个证明基于Alphavirus的复制子颗粒可用于针对商业上重要的牛病原体的犊牛的标准初免/加强免疫接种策略的研究结果。发现:表达牛病毒性腹泻病毒亚型1b E2糖蛋白的复制子颗粒使用对E2具有特异性的多克隆抗体和单克隆抗体,在体外证实了其产生并证实了表达。由颗粒制成的疫苗在Vero细胞中产生,并以初次/加强方案以两种剂量水平施用于无BVDV的犊牛。疫苗接种产生中和抗体效价,该抗体效价在加强疫苗接种后交叉中和1型和2型BVD基因型。此外,高剂量疫苗接种证明对临床疾病有一定的保护作用,并显着降低了由病毒感染引起的白细胞减少症的程度。挑战并减轻小牛的临床疾病。该策略有望为BVDV提供安全有效的疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号